Anders Poulsen

Anders Poulsen

Auto-generated profile, based on publicly available information

Anders Poulsen

Experimental Therapeutics Center, Agency for Science, Technology and Research (A*STAR), Singapore

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Structure
Verified
Journal Article
Closed access
Ajaybabu PobbatiAjaybabu Pobbati
Ajaybabu Pobbati
XHXiao Han
Xiao Han
AHAlvin W. Hung
Alvin W. Hung
WSWei Guang Seetoh
Wei Guang Seetoh
NHNur Huda
Nur Huda
APAnders Poulsen
Anders Poulsen

23 May 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AWAnthony D. William
Anthony D. William
ALAngeline C.-H. Lee
Angeline C.-H. Lee
SBStéphanie Blanchard
Stéphanie Blanchard
APAnders Poulsen
Anders Poulsen
ETEe Ling Teo
Ee Ling Teo
BDBrian W. Dymock
Brian W. Dymock

21 June 2011 in Leukemia
Verified
Journal Article
Open access
SHS Hart
S Hart
KGK C Goh
K C Goh
VNV Novotny-Diermayr
V Novotny-Diermayr
CHC Y Hu
C Y Hu
HHH Hentze
H Hentze
JWJ W Wood
J W Wood
SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 nM for JAK2WT and JAK2V617F, respectively) within the JAK family (IC50=1280, 520 and 50 nM for JAK1, JK3 and TYK2, respectively) and fms-like tyrosine kinase-3 (FLT3; IC50=22 nM). SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs. As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis. SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2V617F-driven disease model. SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a subcutaneous model generated with SET-2 cells derived from a JAK2V617F patient with megakaryoblastic leukemia. Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease. In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models. These favorable properties are now being confirmed in clinical studies in patients with myelofibrosis and lymphoma.

1 December 2006 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
VNVasantha M. Nayagam
Vasantha M. Nayagam
XWXukun Wang
Xukun Wang
YTYong Cheng Tan
Yong Cheng Tan
APAnders Poulsen
Anders Poulsen
KGKee Chuan Goh
Kee Chuan Goh
WSWalter Stünkel
Walter Stünkel
The nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylase SIRT1 has been linked to fatty acid metabolism via suppression of peroxysome proliferator-activated receptor gamma (PPAR-γ) and to inflammatory processes by deacetylating the transcription factor NF-κB. First, modulation of SIRT1 activity affects lipid accumulation in adipocytes, which has an impact on the etiology of a variety of human metabolic diseases such as obesity and insulin-resistant diabetes. Second, activation of SIRT1 suppresses inflammation via regulation of cytokine expression. Using high-throughput screening, the authors identified compounds with SIRT1 activating and inhibiting potential. The biological activity of these SIRT1-modulating compounds was confirmed in cell-based assays using mouse adipocytes, as well as human THP-1 monocytes. SIRT1 activators were found to be potent lipolytic agents, reducing the overall lipid content of fully differentiated NIH L1 adipocytes. In addition, the same compounds have anti-inflammatory properties, as became evident by the reduction of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-α). In contrast, a SIRT1 inhibitory compound showed a stimulatory activity on the differentiation of adipocytes, a feature often linked to insulin sensitization.

10 October 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LYLianbin Yao
Lianbin Yao
NMNurulhuda Mustafa
Nurulhuda Mustafa
ETEng Chong Tan
Eng Chong Tan
APAnders Poulsen
Anders Poulsen
PSPrachi Singh
Prachi Singh
BDBrian W. Dymock
Brian W. Dymock

8 December 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AWAnthony D. William
Anthony D. William
ALAngeline C.-H. Lee
Angeline C.-H. Lee
KGKee Chuan Goh
Kee Chuan Goh
SBStéphanie Blanchard
Stéphanie Blanchard
APAnders Poulsen
Anders Poulsen
BDBrian W. Dymock
Brian W. Dymock